Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Azithromycin

FDA-approved product (capsule, oral), marketed as Azasite, Azithromycin, Zithromax and 1 more.

Registered studies
50+
Lab records
20
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Azithromycin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial conjunctivitis
  • Bacterial disease
  • Cervicitis
  • Chronic bronchitis
  • Chronic obstructive pulmonary disease
  • Cystic fibrosis
  • Eye infection
  • HIV infection
  • Infection
  • Infectious otitis media
  • Otitis media
  • Pelvic Inflammatory Disease
  • Pharyngitis
  • Pneumonia
  • Recurrent tonsillitis
  • Sinusitis
  • and 2 more

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Macrolides; Antibiotics
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01FA10; WHO ATC S01AA26

Repurposing investigation

Azithromycin is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA53.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli89.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae88.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis67.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 7 of 9 lab records
  • E. coli: measured active in 3 of 3 lab records
  • K. pneumoniae: measured active in 8 of 8 lab records
Open Azithromycin in ChEMBL Registered studies below
Show the 20 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Azithromycin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Zithromax EV in Community-Acquired Pneumonia (CAP)

    NCT00137007 · start 2003-11

    Registered record
    Registry ID
    NCT00137007
    Conditions
    Pneumonia
    Interventions
    Azithromycin; Ampicillin/sulbactam
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2003-11
    Completion
    2005-09
    Enrolment
    151

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPneumonia
    InterventionAzithromycin; Ampicillin/sulbactam
    PhasePhase 4
    Registry statusCompleted

  • Telithromycin: in the Treatment of Acute Exacerbation of Chronic Bronchitis in Adult Outpatients With COPD

    NCT00538148 · start 2002-11

    Registered record
    Registry ID
    NCT00538148
    Conditions
    Bronchitis, Chronic
    Interventions
    Telithromycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2002-11
    Completion
    2004-09
    Enrolment
    668

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBronchitis, Chronic
    InterventionTelithromycin
    PhasePhase 4
    Registry statusCompleted

  • Study of Azithromycin to Prevent Recurrent Trichiasis Following Surgery in Ethiopia

    NCT00347776 · start 2001-08

    Registered record
    Registry ID
    NCT00347776
    Conditions
    Trichiasis
    Interventions
    azithromycin; topical tetracycline
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2001-08
    Completion
    2006-12
    Enrolment
    1,452

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTrichiasis
    Interventionazithromycin; topical tetracycline
    PhasePhase 4
    Registry statusCompleted

  • Azithromycin/Bicillin Syphilis

    NCT00031499 · start 2000-06

    Registered record
    Registry ID
    NCT00031499
    Conditions
    Syphilis
    Interventions
    Azithromycin; Benzathine Penicillin; Doxycycline
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2000-06
    Completion
    2009-03
    Enrolment
    593

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSyphilis
    InterventionAzithromycin; Benzathine Penicillin; Doxycycline
    PhasePhase 3
    Registry statusCompleted

  • Azithromycin Combination Therapy for Malaria

    NCT00299208

    Registered record
    Registry ID
    NCT00299208
    Conditions
    Plasmodium Falciparum Malaria
    Interventions
    Artesunate; Azithromycin; Quinine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    Not recorded
    Completion
    2005-07
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPlasmodium Falciparum Malaria
    InterventionArtesunate; Azithromycin; Quinine
    PhasePhase 2
    Registry statusCompleted